Redhill Stock Story

RDHL

Stock

USD 1.07 0.09 9.18%

Macroaxis Story

If you have been keeping an eye on Redhill Biophrma you know that now may not be the best time to buy. The company current chance of distress is under 46 percent. Will stakeholders continue to be optimistic, or should we expect a sell-off?

Published over two months ago

View all stories for Redhill Biophrma | View All Stories

Are Redhill Biophrma (NASDAQ:RDHL) sluggish technical indicators contributing to the new pull down?

The company holds a Beta of 2.8626, which implies a somewhat significant risk relative to the market. Let's try to break down what Redhill's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Redhill Biophrma will likely underperform. Even though it is essential to pay attention to Redhill Biophrma ADR current trending patterns, it is always good to be careful when utilizing equity existing price patterns. Our philosophy towards forecasting any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Redhill Biophrma ADR exposes twenty-seven different technical indicators, which can help you to evaluate its performance. Redhill Biophrma ADR has an expected return of -0.44%. Please be advised to check Redhill Biophrma ADR jensen alpha, semi variance, day typical price, as well as the relationship between the maximum drawdown and accumulation distribution to decide if Redhill Biophrma ADR performance from the past will be repeated at some point in the near future.

Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Redhill Biophrma income statement, its balance sheet, and the statement of cash flows. Potential Redhill Biophrma investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Redhill Biophrma investors may use each financial statement separately, they are all related. The changes in Redhill Biophrma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Redhill Biophrma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

The goal of Redhill Biophrma fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Redhill Biophrma performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Redhill Biophrma shares is the value that is considered the true value of the share. If the intrinsic value of Redhill is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Redhill Biophrma.

Please read more on our fundamental analysis page.

Watch out for price decline

Please consider monitoring Redhill Biophrma on a daily basis if you are holding a position in it. Redhill Biophrma is trading at a penny-stock level, and the possibility of delisting is much higher compared to other equities. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Redhill Biophrma stock to be traded above the $1 level to remain listed. If Redhill Biophrma stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

Are Redhill Biophrma Earnings Expected to grow?

The future earnings power of Redhill Biophrma involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Redhill Biophrma factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Redhill Biophrma stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Redhill expected earnings.

How does Redhill utilize its cash?

To perform a cash flow analysis of Redhill Biophrma, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Redhill Biophrma is receiving and how much cash it distributes out in a given period. The Redhill Biophrma cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

What is the case for Redhill Biophrma Investors

Redhill Biophrma ADR reported the previous year's revenue of 85.76 M. Net Loss for the year was (97.74 M) with profit before overhead, payroll, taxes, and interest of 45.25 M.

Our take on Redhill Biophrma small pull down

Redhill Biophrma new standard deviation upsurges over 7.2. Redhill Biophrma ADR is displaying above-average volatility over the selected time horizon. Investors should scrutinize Redhill Biophrma ADR independently to ensure intended market timing strategies are aligned with expectations about Redhill Biophrma volatility. Redhill Biophrma ADR is a potential penny stock. Although Redhill Biophrma may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Redhill Biophrma ADR. We encourage investors to look for the signals such us email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Redhill instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.

Our Final Perspective on Redhill Biophrma

While some other firms in the drug manufacturers—specialty & generic industry are either recovering or due for a correction, Redhill Biophrma may not be performing as strong as the other in terms of long-term growth potentials. All things considered, as of the 4th of June 2022, we believe that at this point, Redhill Biophrma is relatively risky with close to average probability of distress within the next 2 years. From a slightly different point of view, the entity appears to be undervalued. Our primary 90 days 'Buy-vs-Sell' recommendation on the company is Hold.

Editorial Staff

Ellen Johnson is a Member of Macroaxis Editorial Board. Ellen covers public companies in North America, focusing primarily on valuation and volatility. Six years of experience in predictive investment analytics and risk management. View Profile

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Redhill Biophrma ADR. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2022 Macroaxis LLC